RELATED: Revlimid, Rituxan combination delivers new lymphoma nod—and a potential $600M boost for Celgene Celgene is bringing its own set of oncology challenges to the table in the merger. One worry is its $9.7 billion-per-year multiple myeloma treatment Revlimid, which has faced patent challenges that could cause the drug to lose its market exclusivity earlier than investors are expecting. That was the main concern, in fact, of institutional investors like Starboard Value that tried to scuttle the BMS deal. And one Revlimid generic is already on the market in Europe.